All In Biotech

Drug Trial Radar · NCT07818915

A Study to Investigate Pharmacokinetics (PK), Safety, and Tolerability of VH4367310 in Healthy Adult Participants

A Phase 1 Double-blind (Sponsor-unblinded), Placebo-controlled, Randomized, Single Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VH4367310 Administered to Healthy Adult Participants

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 112 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

112

Planned (sponsor's estimate)

Start

Sep 15, 2026

Primary completion

Dec 26, 2028

Study completion Dec 26, 2028

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
Sep 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study evaluates the PK, safety, and tolerability of a single increasing dose of VH4367310, a cabotegravir (CAB) prodrug, when administered intramuscularly in healthy adult participants 18 to 55 years of age.

Conditions

  • HIV Infections

Interventions

  • VH4367310Drug

    VH4367310 will be administered intramuscularly.

  • PlaceboDrug

    Placebo will be administered intramuscularly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration time curve from time zero to last quantifiable time point (AUC0-tlast) of VH4367310 and CABTime frame: Up to Week 72
  2. Maximum observed plasma concentration (Cmax) of VH4367310 and CABTime frame: Up to Week 72
  3. Time to maximum observed plasma concentration (Tmax) of VH4367310 and CABTime frame: Up to Week 72
  4. Number of participants with drug-related adverse events (AEs)Time frame: Up to Week 72
  5. Number of participants with AEs as per severityTime frame: Up to Week 72
  6. Number of participants with drug-related serious adverse events (SAEs)Time frame: Up to Week 72

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Glendale, California · Recruiting

  • GSK Investigational Site

    Baltimore, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.